Search
for
Sort by
Research 30 of 1000+
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Under Development JAK Inhibitors for Dermatologic Diseases
- Jak inhibitors in the treatment of alopecia areata - a literature review
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- The Role of Janus Kinase Inhibitors in Dermatology
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
- Janus Kinase Inhibitors - A next generation treatment in Dermatology
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Janus kinase inhibitors: An innovative treatment for alopecia areata
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- Treatment of alopecia areata with JAK inhibitors
- The JAK/STAT signaling pathway: from bench to clinic
- Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- The role of janus kinases in the treatment of autoimmune skin diseases
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling